CD4 AND CD8 REFERENCE COUNTS IN NORMAL HEALTHY SOUTH-INDIAN ADULTS
Dear editor, As we know, the CD4 cell count is the best indicator of the immediate state of immunologic competence of the patient with HIV infection and these are one of the most widely used surrogate markers for monitoring disease progression and initiating therapy for HIV infected individuals. Because of drastic cut down in the prices of antiretroviral drugs, the antiretroviral therapy has become more affordable in India. Therefore, it is important to know the baseline CD4 count in normal healthy individuals of that locality, as CD4 counts differ from one locality to other and among different ethnic groups. Estimation of CD4 and CD8 cells continues to be an important marker for the monitoring of HIV infected patients especially in developing countries. [1] The gold standard method for detection of CD4 /CD8 count is ß ow-cytometry. But its high initial investments and reagent costs and need for trained personnel, make it unaffordable to most centres in developing countries. Many alternative methods for estimation of CD4/CD8 counts have been developed. [2] Previous studies have shown that the immunoenzyme assay results well correlated with those of ß ow cytometric analysis. The easy availability, low cost, rapid performance, make it a user-friendly test and an efÞ cient alternative to ß ow cytometry. [1] We used the Capcellia CD4 /CD8 whole blood assay for detection of CD4/CD8 T Lymphocytes which is an enzyme immunoassay and provides absolute counts of CD4 + and CD8 + T cell counts in peripheral blood.
The present study was carried out in the Department of Microbiology, Kasturba Medical College, Manipal. Study period was for 18 months from May 2001 to November 2002. A total of 30 healthy adults of both sexes belonging to 20-25 years of age consisting of medical students and nurses were included in the study. The peripheral CD4 + /CD8 + T-lymphocyte counts were detected in these individuals, using CAPCELLIA CD4/CD8 whole blood assay, according to the standard protocol. [1] Exclusion criteria for these individuals were, a) Any minor illness in the past one month b) Any major illness in the past six months c) Individuals who took any vaccination in the past six months d) Pregnant women.
All these healthy individuals were also screened for anti-HIV antibodies by licensed HIV antibody detection kit. Informed consent was obtained from all individuals. Fresh venous blood (2 mL) was collected between 8 am to 10 am, in a vacutainer with EDTA and the test was performed on the same day. A standard curve corresponding to assay was drawn on each graph. Each curve was plotted from Þ ve absorbance values experimentally determined from the assay. The absorbance values were carried over on the calibration curve and T cell concentration (cells/μL of blood) was calculated for each sample. Data were subjected to Microsoft-excel for SD and graph. The mean CD4 count was found to be 834.6 ± 222.2 and mean CD8 count was found to be 579.3 ± 195.6 as shown in the Figure. CD4 counts normally differ from one locality to other, and vary among different ethnic groups. [3] The mean CD4 count among normal Indians is signiÞ cantly lower than that in the Western population. [4] It is important to know the baseline CD4 count to draw a criterion for consideration of therapy and we cannot use Western standards for treatment in Indian patients. About the CD4 count of normal healthy individuals two reports are available from south India. In one study from Vellore, it was observed that the mean CD4 T cell counts in normal healthy individuals were 1048 ± 210 and for CD8 cells were 595 ± 211. In the second study [5] from Pune the mean CD4 count of 777 cells/μL (n = 21) was observed. In the North East study [6] at Manipur, the absolute CD4 count in normal healthy controls was found to be 848 ± 395 and CD8 T lymphocytes counts were 427 ± 123. There are also reports of CD4 counts of less than 500 cells/μL in normal healthy individuals. [4] In our study, the mean reference count for CD4 cells was found to be 835 ± 222 and for 
EXTENDED SPECTRUM BETA LACTAMASE (ESBL) PRODUCING ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE IN DIABETIC FOOT INFECTION
Dear editor, Trauma, leading to infection is a common sequel of diabetic foot ulceration, which, once established, progressively worsens and becomes more difÞ cult to treat. Extended spectrum β lactamases (ESBLs) are the derivatives of common ß-lactamases (TEM and SHV ß-lactamases) that have undergone one or more amino acid substitutions near the active site of the enzyme, thus increasing their afÞ nity and the hydrolytic activity against third generation cephalosporins and monobactams. [1] Production of ESBL enzymes is either chromosomally mediated or plasmid mediated. [2] The majority of ESBL producing strains are Klebsiella pneumoniae, Escherichia coli and Klebsiella oxytoca. [1] This study was carried out to Þ nd out ESBL producing E.coli and K.pneumoniae in diabetic foot infection with type 2 diabetes mellitus and the clinical outcome of these patients.
Over a one year period from January-December 2006, 191 samples (tissue 116, wound swab 75) were collected from indoor patients admitted at S.L. Raheja Hospital, tertiary care hospital for diabetic patients. Patients with nonhealing diabetic foot ulcers for two weeks with empirical antibiotic treatment were included in the study. The samples were processed, identiÞ ed and tested for antibiotic sensitivity test based on standard laboratory technique according to Clinical and Laboratory Standards Institute (CLSI) guidelines [3] with commercially available discs (Hi Media) on Muller Hinton agar plates.
ESBL producer was identiÞ ed if there was ≥5 mm increase in zone diameter of ceftazidime/clavulanate disc than that of ceftazidime disc alone. Escherichia. coli ATCC 25922 was used as negative control.
From 43 E.coli isolated, ESBL production was observed in 46.51% whereas from 27 K.pneumoniae isolated, ESBL production was found in 44.44%. Maximum ESBL producers were isolated from tissue samples. A combination of carbapenem, amikacin and piperacillin/tazobactam was given to the patients. The mean hospital stay for the indoor patients was 20 days. There was no mortality associated with this infection.
There is paucity of Indian data on the ESBL producing pathogens in diabetic foot infection. In a study conducted in 2001, the prevalence was only 6% amongst E.coli isolates. [4] Kapil et al, have reported 54.5 % E.coli isolates to be ESBL producers. [5] We report overall 46.51% E.coli and 44.44% K.pneumoniae isolates to be ESBL producers.
Thus, the prevalence of ESBLs among members of Enterobacteriaceae constitutes a serious threat to current beta-lactam therapy leading to treatment failure in diabetic foot infection.
